TNFRSF4 and systemic lupus erythematosus: Additionally, in a recent study of a type I interferon-accelerated NZB/NZW.F1 mice model, anti-OX40 treatment significantly delayed severe proteinuria onset and improved survival [54], suggesting the potential therapeutic benefit of targeting this axis in SLE.